162 related articles for article (PubMed ID: 20308121)
1. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
Deighton C; Hyrich K; Ding T; Ledingham J; Lunt M; Luqmani R; Kiely P; Bukhari M; Abernethy R; Ostor A; Bosworth A; Gadsby K; McKenna F; Finney D; Dixey J;
Rheumatology (Oxford); 2010 Jun; 49(6):1197-9. PubMed ID: 20308121
[No Abstract] [Full Text] [Related]
2. Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines.
Hur JW; Choe JY; Kim DW; Kim HA; Kim SH; Kim WU; Kim YS; Lee HS; Lee SH; Park SH; Park W; Park YB; Suh CH; Shim SC; Song YW; Yoon BY; Yu DY; Yoo DH
Rheumatol Int; 2015 Nov; 35(11):1817-23. PubMed ID: 26342296
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness estimates reported for tumor necrosis factor blocking agents in rheumatoid arthritis refractory to methotrexate--a brief summary.
Maetzel A
J Rheumatol Suppl; 2005 Jan; 72():51-3. PubMed ID: 15660469
[TBL] [Abstract][Full Text] [Related]
4. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.
Ding T; Ledingham J; Luqmani R; Westlake S; Hyrich K; Lunt M; Kiely P; Bukhari M; Abernethy R; Bosworth A; Ostor A; Gadsby K; McKenna F; Finney D; Dixey J; Deighton C; ;
Rheumatology (Oxford); 2010 Nov; 49(11):2217-9. PubMed ID: 20837498
[No Abstract] [Full Text] [Related]
5. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
Bukhari M; Abernethy R; Deighton C; Ding T; Hyrich K; Lunt M; Luqmani R; Kiely P; Bosworth A; Ledingham J; Ostör A; Gadsby K; McKenna F; Finney D; Dixey J;
Rheumatology (Oxford); 2011 Dec; 50(12):2311-3. PubMed ID: 21546351
[No Abstract] [Full Text] [Related]
6. Clinical image: hidden costs of anti-tumor necrosis factor alpha therapy.
Mulherin D; Sheeran TP
Arthritis Rheum; 2003 Mar; 48(3):868. PubMed ID: 12632461
[No Abstract] [Full Text] [Related]
7. NICE guidance on rheumatoid arthritis: implications and challenges for rheumatologists.
Walker D; Hall S
Rheumatology (Oxford); 2010 Apr; 49(4):619-20. PubMed ID: 20032225
[No Abstract] [Full Text] [Related]
8. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology.
Fautrel B; Flipo RM; Saraux A
Rheumatology (Oxford); 2008 Nov; 47(11):1698-703. PubMed ID: 18794185
[TBL] [Abstract][Full Text] [Related]
9. NICE guidelines on anti-tumor necrosis factor therapy for RA.
Scott DL; Steer S
Nat Clin Pract Rheumatol; 2009 Jan; 5(1):16-7. PubMed ID: 19048006
[No Abstract] [Full Text] [Related]
10. Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria.
Geens E; Geusens P; Vanhoof J; Berghs H; Praet J; Esselens G; Lens S; Dufour JP; Vandenberghe M; Van Mullem X; Westhovens R; Verschueren P
Rheumatology (Oxford); 2009 May; 48(5):546-50. PubMed ID: 19254920
[TBL] [Abstract][Full Text] [Related]
11. The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy.
Bingham SJ; Buch MH; Tennant A; Emery P
Rheumatology (Oxford); 2004 Mar; 43(3):364-8. PubMed ID: 14657509
[TBL] [Abstract][Full Text] [Related]
12. If it works why can't we have it? Sequential anti-TNF therapy in the UK.
Deighton C
Rheumatology (Oxford); 2010 Dec; 49(12):2235-6. PubMed ID: 20685801
[No Abstract] [Full Text] [Related]
13. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).
Deighton CM; George E; Kiely PD; Ledingham J; Luqmani RA; Scott DG
Rheumatology (Oxford); 2006 Jun; 45(6):649-52. PubMed ID: 16527881
[No Abstract] [Full Text] [Related]
14. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
Kulp W; Greiner W; Graf von der Schulenburg JM
Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
[No Abstract] [Full Text] [Related]
15. Anti-tumour necrosis factor therapy in the West Midlands.
Bartram D; Sheeran T; Price T; Mulherin D
Rheumatology (Oxford); 2004 Mar; 43(3):400; author reply 400-1. PubMed ID: 14963219
[No Abstract] [Full Text] [Related]
16. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
Kavanaugh A; Cohen S; Cush JJ
J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
[No Abstract] [Full Text] [Related]
17. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
Metcalfe S; Moodie P; Grocott R; Wilkinson T
N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
[No Abstract] [Full Text] [Related]
18. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
Kavanaugh A
Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
[No Abstract] [Full Text] [Related]
19. [TNF-inhibitors slow down joint destruction in rheumatoid arthritis. No cure, but dramatic relief of symptoms].
Wollheim FA
Lakartidningen; 2001 May; 98(21):2560-2. PubMed ID: 11433990
[No Abstract] [Full Text] [Related]
20. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study.
Marshall NJ; Wilson G; Lapworth K; Kay LJ
Rheumatology (Oxford); 2004 Aug; 43(8):1034-8. PubMed ID: 15150436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
